Precision medicine

#Innovation #IXICO #Neuroscience #Precision medicine #Technology

The resurgence of neuroscience

Bram Goorden, CEO, IXICO, looks at why precision medicine is the next frontier for neuroscience. For much of the early 2000s, neuroscience was one of the pharmaceutical industry’s most challenging therapeutic areas. Clinical failures accumulated and investors increasingly favoured oncology, where biomarker-driven drug development… Read More

#Exclusive Content

#Genetics #Natural killer cells #Neuroscience #Parkinson's disease #Precision medicine

Precision therapies for Parkinson’s Disease

In this contribution to the Fall 2026 issue of DDW, Dr Andrew French PhD, Dr Richard Boyd PhD, Prof Alice Pébay PhD, and Prof Alan Trounson PhD, explore emerging research into NK cell-derived extracellular vesicles (NK-EVs) as a potential therapeutic platform for neurodegenerative disease. Neurodegenerative diseases… Read More

#Exclusive Content

Targetted cancer therapy
#Interview #Oncology #Precision medicine #Racura Oncology

Why G‑quadruplex biology is back and what it means for MYC‑driven cancers

Racura Oncology recently raised AU$34.3 (US$24.31) million to fund its RC220 clinical programmes in acute myeloid leukaemia (AML), epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer, and anthracycline cardioprotection in solid tumour patients.  Diana Turner speaks to Dr Peter Smith, Executive Chair of Racura, about… Read More

#Cancer Research #Exclusive Content

#AI #Cancer research #Cervical cancer #Clinical trial #Colorectal cancer #Genetics / genomics #Head and neck cancer #MHRA #Obesity #Pistoia Alliance #Precision medicine #University College London #University of Cambridge #Weight loss

DDW Highlights: 9 June 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, a cancer drug demonstrated it could reduce tumours by as much as… Read More

#Podcasts

#AI #Cancer research #Cervical cancer #Clinical trial #Colorectal cancer #Genetics / genomics #Head and neck cancer #MHRA #Obesity #Pistoia Alliance #Precision medicine #University College London #University of Cambridge #Weight loss

This week in Drug Discovery (1 June – 5 June) 

News round-up for 1 June – 5 June by Bruno Quinney, Content Team at DDW.  This week, a cancer drug has demonstrated it could reduce tumours by as much as 55%. Elsewhere, AI has been a recurrent theme in both clinical trials and drug development.   The top stories:… Read More

#News

#Breast cancer #Genetics / genomics #Oncology #Precision medicine #University College London

Gene test guides more personalised breast cancer treatment

Many people with breast cancer can safely avoid chemotherapy with the use of a gene test, a large international clinical trial led by University College London (UCL) has found.  The OPTIMA trial (Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis) followed more than 4,400 patients… Read More

#Cancer Research #News

Proteomics
#Biotech #Oncology #Precision medicine #Proteomics

Nomic and Broad Clinical Labs to build proteomics platform 

Biotechnology company Nomic Bio has announced a partnership with Broad Clinical Labs (BCL) to build a scalable proteomics platform.  The organisations will look to integrate Nomic’s Omni 1000 solution into BCL’s existing capabilities to develop new application-specific solutions.   Based on nELISA technology, Nomic says Omni 1000 measures… Read More

#News

#Coiled Therapeutics #Drug discovery #Oncology #Precision medicine

Coiled Therapeutics completes transition to clinical-stage company

Coiled Therapeutics, previously Roquefort Therapeutics, has completed the acquisition of the exclusive worldwide licence to AO-252 and admitted its shares to trading on the AIM Market of the London Stock Exchange.  Admission follows a successful fundraise of £8.5 ($11.3) million through the issue of 85,000,000 New Ordinary… Read More

#Business & Investment #News #Start-up Zone

#AI #Oncology #Precision medicine

Collaboration to advance precision oncology therapy 

Oncology company One-carbon Therapeutics has entered a strategic collaboration with precision medicine company Tempus AI to advance precision oncology development.  The collaboration will leverage Tempus’ proprietary, de-identified multimodal database and bioinformatics knowledge to advance molecular insights supporting the clinical development of TH9619.  TH9619, developed by… Read More

#Business & Investment #News

Metabolomics
#Autoimmune disease #Drug discovery #Lipidomics #Metabolomics #Precision medicine #Webinar

Uncover novel biomarkers using metabolomic and lipidomic profiling

This webinar, hosted by DDW and supported by Evotec, introduces untargeted metabolomics and lipidomics analyses, which are designed to accelerate research in complex biological systems. The webinar begins with an overview of the principles behind untargeted approaches, highlighting their importance in capturing a comprehensive molecular snapshot without prior assumptions. Read More

Webinar date:
Supported by Evotec
#News

#Autoimmune disease #Drug discovery #Lipidomics #Metabolomics #Precision medicine #Webinar

Webinar: The importance of untargeted approaches to discovery

This webinar, hosted by DDW and supported by Evotec, introduces untargeted metabolomics and lipidomics analyses, which are designed to accelerate research in complex biological systems. The webinar begins with an overview of the principles behind untargeted approaches, highlighting their importance in capturing a comprehensive molecular snapshot without prior assumptions. Read More

Webinar date:
Supported by Evotec
#News

#Autoimmune disease #Drug discovery #Lipidomics #Metabolomics #Precision medicine #Webinar

Webinar: Discover untargeted metabolomics and lipidomics approaches

This webinar, hosted by DDW and supported by Evotec, introduces untargeted metabolomics and lipidomics analyses, which are designed to accelerate research in complex biological systems. The webinar begins with an overview of the principles behind untargeted approaches, highlighting their importance in capturing a comprehensive molecular snapshot without prior assumptions. Read More

Webinar date:
Supported by Evotec
#News

Synthetic DNA
#Drug development #Genomics #Precision medicine

6-Base sequencing: A tool for better drug development 

Tom Charlesworth, Director of Marketing Strategy and Corporate Development at biomodal examines how 6-base sequencing can unlock advancements in precision medicine.  Call it precision medicine, Genomics 3.0, or the age of multi-omics. However you choose to describe it, the underlying meaning is the same: Our ability to collect and… Read More

#Exclusive Content

Biomarkers concept
#Autoimmune disease #Drug discovery #Lipidomics #Metabolomics #Precision medicine #Webinar

Webinar: Accelerate your research in complex biological systems

This webinar, hosted by DDW and supported by Evotec, introduces untargeted metabolomics and lipidomics analyses, which are designed to accelerate research in complex biological systems. The webinar begins with an overview of the principles behind untargeted approaches, highlighting their importance in capturing a comprehensive molecular snapshot without prior assumptions. Read More

Webinar date:
Supported by Evotec
#News